248 related articles for article (PubMed ID: 16360673)
1. Schizophrenia.
Morrison PD; Murray RM
Curr Biol; 2005 Dec; 15(24):R980-4. PubMed ID: 16360673
[No Abstract] [Full Text] [Related]
2. Schizophrenia: an illness of distorted reality.
Dean B
Biologist (London); 2000 Sep; 47(4):202-6. PubMed ID: 11153121
[TBL] [Abstract][Full Text] [Related]
3. Schizophrenia.
Freedman R
N Engl J Med; 2003 Oct; 349(18):1738-49. PubMed ID: 14585943
[No Abstract] [Full Text] [Related]
4. Alterations of dopamine and serotonin transmission in schizophrenia.
Remington G
Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
[TBL] [Abstract][Full Text] [Related]
5. Dual constraints on synapse formation and regression in schizophrenia: neuregulin, neuroligin, dysbindin, DISC1, MuSK and agrin.
Bennett A O MR
Aust N Z J Psychiatry; 2008 Aug; 42(8):662-77. PubMed ID: 18622774
[TBL] [Abstract][Full Text] [Related]
6. Clozapine treatment of schizophrenia.
Pickar D; Hsiao JK
JAMA; 1995 Sep; 274(12):981-3. PubMed ID: 7674530
[No Abstract] [Full Text] [Related]
7. [Susceptibility genes for schizophrenia].
Itokawa M; Yoshikawa T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():437-40. PubMed ID: 16416830
[No Abstract] [Full Text] [Related]
8. Antipsychotic-induced movement disorders - forgotten but not gone.
Weiden PJ
Acta Psychiatr Scand; 2008 Jun; 117(6):401-2. PubMed ID: 18479315
[No Abstract] [Full Text] [Related]
9. What have the genomics ever done for the psychoses?
Gill M; Donohoe G; Corvin A
Psychol Med; 2010 Apr; 40(4):529-40. PubMed ID: 19818200
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder.
Gogos JA
Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27.
Meltzer HY
Psychopharmacology (Berl); 2002 Aug; 163(1):1-3. PubMed ID: 12185394
[No Abstract] [Full Text] [Related]
12. Dopamine and schizophrenia.
Crow TJ; Johnstone EC; Longden A; Owen F
Adv Biochem Psychopharmacol; 1978; 19():301-9. PubMed ID: 29450
[No Abstract] [Full Text] [Related]
13. Decoding schizophrenia.
Javitt DC; Coyle JT
Sci Am; 2004 Jan; 290(1):48-55. PubMed ID: 14682038
[No Abstract] [Full Text] [Related]
14. Schizophrenia.
Bladessarini RJ
N Engl J Med; 1977 Nov; 297(18):988-95. PubMed ID: 20577
[No Abstract] [Full Text] [Related]
15. [Schizophrenia and dopamine (author's transl)].
Toru M
Tanpakushitsu Kakusan Koso; 1978; 23(4):303-16. PubMed ID: 26107
[No Abstract] [Full Text] [Related]
16. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia.
Hattori S; Murotani T; Matsuzaki S; Ishizuka T; Kumamoto N; Takeda M; Tohyama M; Yamatodani A; Kunugi H; Hashimoto R
Biochem Biophys Res Commun; 2008 Aug; 373(2):298-302. PubMed ID: 18555792
[TBL] [Abstract][Full Text] [Related]
17. Integrating the neurobiology of schizophrenia. Preface.
Abi-Dargham A; Guillin O
Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
[No Abstract] [Full Text] [Related]
18. A critique of the dopamine hypothesis of schizophrenia and psychosis.
Moncrieff J
Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420
[TBL] [Abstract][Full Text] [Related]
19. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment of schizophrenia.
Silverstone T
N Z Med J; 1994 Apr; 107(976):145-6. PubMed ID: 7909363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
